FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124358959> ?p ?o ?g. }

• W2124358959 endingPage "5106" @default.
• W2124358959 startingPage "5099" @default.
• W2124358959 abstract "ABSTRACT Expanded options for treatments directed against pathogens that can be used for bioterrorism are urgently needed. Treatment regimens directed against such pathogens can be identified only by using data derived from in vitro and animal studies. It is crucial that these studies reliably predict the efficacy of proposed treatments in humans. The objective of this study was to identify a levofloxacin treatment regimen that will serve as an effective therapy for Bacillus anthracis infections and postexposure prophylaxis. An in vitro hollow-fiber infection model that replicates the pharmacokinetic profile of levofloxacin observed in humans (half-life [ t 1/2 ], 7.5 h) or in animals, such as the mouse or the rhesus monkey ( t 1/2 , ∼2 h), was used to evaluate a proposed indication for levofloxacin (500 mg once daily) for the treatment of Bacillus anthracis infections. The results obtained with the in vitro model served as the basis for the doses and the dose schedules that were evaluated in the mouse inhalational anthrax model. The effects of levofloxacin and ciprofloxacin treatment were compared to those of no treatment (untreated controls). The main outcome measure in the in vitro hollow-fiber infection model was a persistent reduction of culture density (≥4 log 10 reduction) and prevention of the emergence of levofloxacin-resistant organisms. In the mouse inhalational anthrax model the main outcome measure was survival. The results indicated that levofloxacin given once daily with simulated human pharmacokinetics effectively sterilized Bacillus anthracis cultures. By using a simulated animal pharmacokinetic profile, a once-daily dosing regimen that provided a human-equivalent exposure failed to sterilize the cultures. Dosing regimens that “partially humanized” levofloxacin exposures within the constraints of animal pharmacokinetics reproduced the antimicrobial efficacy seen with human pharmacokinetics. In a mouse inhalational anthrax model, once-daily dosing was significantly inferior (survival end point) to regimens of dosing every 12 h or every 6 h with identical total daily levofloxacin doses. These results demonstrate the predictive value of the in vitro hollow-fiber infection model with respect to the success or the failure of treatment regimens in animals. Furthermore, the model permits the evaluation of treatment regimens that “humanize” antibiotic exposures in animal models, enhancing the confidence with which animal models may be used to reliably predict the efficacies of proposed antibiotic treatments in humans in situations (e.g., the release of pathogens as agents of bioterrorism or emerging infectious diseases) where human trials cannot be performed. A treatment regimen effective in rhesus monkeys was identified." @default.
• W2124358959 created "2016-06-24" @default.
• W2124358959 creator A5004760042 @default.
• W2124358959 creator A5010227649 @default.
• W2124358959 creator A5011691262 @default.
• W2124358959 creator A5013161097 @default.
• W2124358959 creator A5020148591 @default.
• W2124358959 creator A5022556893 @default.
• W2124358959 creator A5028334845 @default.
• W2124358959 creator A5031270415 @default.
• W2124358959 creator A5036512885 @default.
• W2124358959 creator A5048297658 @default.
• W2124358959 date "2005-12-01" @default.
• W2124358959 modified "2023-10-07" @default.
• W2124358959 title "Effective Antimicrobial Regimens for Use in Humans for Therapy of <i>Bacillus anthracis</i> Infections and Postexposure Prophylaxis" @default.
• W2124358959 cites W11063304 @default.
• W2124358959 cites W1983076976 @default.
• W2124358959 cites W2003536511 @default.
• W2124358959 cites W2012527270 @default.
• W2124358959 cites W2014662468 @default.
• W2124358959 cites W2023714833 @default.
• W2124358959 cites W2024995999 @default.
• W2124358959 cites W2025771032 @default.
• W2124358959 cites W2034503551 @default.
• W2124358959 cites W2035031389 @default.
• W2124358959 cites W2067130929 @default.
• W2124358959 cites W2079691262 @default.
• W2124358959 cites W2103989683 @default.
• W2124358959 cites W2109396161 @default.
• W2124358959 cites W2113717321 @default.
• W2124358959 cites W2121019748 @default.
• W2124358959 cites W2128560257 @default.
• W2124358959 cites W2137878800 @default.
• W2124358959 cites W2146732427 @default.
• W2124358959 cites W2147264575 @default.
• W2124358959 cites W2166840599 @default.
• W2124358959 cites W2168147536 @default.
• W2124358959 cites W2171003220 @default.
• W2124358959 cites W2172212022 @default.
• W2124358959 cites W4249066751 @default.
• W2124358959 cites W4285719527 @default.
• W2124358959 cites W4298221064 @default.
• W2124358959 doi "https://doi.org/10.1128/aac.49.12.5099-5106.2005" @default.
• W2124358959 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1315931" @default.
• W2124358959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16304178" @default.
• W2124358959 hasPublicationYear "2005" @default.
• W2124358959 type Work @default.
• W2124358959 sameAs 2124358959 @default.
• W2124358959 citedByCount "64" @default.
• W2124358959 countsByYear W21243589592012 @default.
• W2124358959 countsByYear W21243589592013 @default.
• W2124358959 countsByYear W21243589592014 @default.
• W2124358959 countsByYear W21243589592015 @default.
• W2124358959 countsByYear W21243589592016 @default.
• W2124358959 countsByYear W21243589592017 @default.
• W2124358959 countsByYear W21243589592019 @default.
• W2124358959 countsByYear W21243589592020 @default.
• W2124358959 countsByYear W21243589592021 @default.
• W2124358959 countsByYear W21243589592023 @default.
• W2124358959 crossrefType "journal-article" @default.
• W2124358959 hasAuthorship W2124358959A5004760042 @default.
• W2124358959 hasAuthorship W2124358959A5010227649 @default.
• W2124358959 hasAuthorship W2124358959A5011691262 @default.
• W2124358959 hasAuthorship W2124358959A5013161097 @default.
• W2124358959 hasAuthorship W2124358959A5020148591 @default.
• W2124358959 hasAuthorship W2124358959A5022556893 @default.
• W2124358959 hasAuthorship W2124358959A5028334845 @default.
• W2124358959 hasAuthorship W2124358959A5031270415 @default.
• W2124358959 hasAuthorship W2124358959A5036512885 @default.
• W2124358959 hasAuthorship W2124358959A5048297658 @default.
• W2124358959 hasBestOaLocation W21243589591 @default.
• W2124358959 hasConcept C112705442 @default.
• W2124358959 hasConcept C126322002 @default.
• W2124358959 hasConcept C2777288759 @default.
• W2124358959 hasConcept C2778049240 @default.
• W2124358959 hasConcept C2778512257 @default.
• W2124358959 hasConcept C2780239966 @default.
• W2124358959 hasConcept C2781276175 @default.
• W2124358959 hasConcept C2781413609 @default.
• W2124358959 hasConcept C4937899 @default.
• W2124358959 hasConcept C501593827 @default.
• W2124358959 hasConcept C523546767 @default.
• W2124358959 hasConcept C54355233 @default.
• W2124358959 hasConcept C71924100 @default.
• W2124358959 hasConcept C86803240 @default.
• W2124358959 hasConcept C89423630 @default.
• W2124358959 hasConcept C98274493 @default.
• W2124358959 hasConceptScore W2124358959C112705442 @default.
• W2124358959 hasConceptScore W2124358959C126322002 @default.
• W2124358959 hasConceptScore W2124358959C2777288759 @default.
• W2124358959 hasConceptScore W2124358959C2778049240 @default.
• W2124358959 hasConceptScore W2124358959C2778512257 @default.
• W2124358959 hasConceptScore W2124358959C2780239966 @default.
• W2124358959 hasConceptScore W2124358959C2781276175 @default.
• W2124358959 hasConceptScore W2124358959C2781413609 @default.
• W2124358959 hasConceptScore W2124358959C4937899 @default.
• W2124358959 hasConceptScore W2124358959C501593827 @default.
• W2124358959 hasConceptScore W2124358959C523546767 @default.

• next